Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is a clinical research study of interferon (IFN) plus chemotherapy with the standard
combination of Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD). The treatment will be
given to patients with Hodgkin's disease. The study will look at whether adding IFN to ABVD
improves the immune response against Hodgkin's disease, and will determine whether the
toxicity of ABVD is increased by adding IFN.